Steve Xu, MD, MSc, FAAD

While FDA action is awaited, dermatology clinicians can suggest BPO-free alternatives such as retinoids, salicylic acid, and more.

Nuogen Pharma’s mission is to deliver the first FDA-approved anti-itch medication for chronic pruritus of unknown origin (CPUO) and other chronic itch conditions.

Hans Hofland, Ph.D, and Dr. Steve Xu shine a spotlight on Dermira and its novel topical medicine indicated for primary axillary hyperhidrosis in patients 9 years of age and older.

In this month's Innovation article, Steve Xu, M.D., FAAD, highlights a company and innovator who are using artificial intelligence to augment physician decision-making, not replace it. ƒ

Drs. Lilit Garibyan, Steve Xu and Kachiu C. Lee highlight a grassroots initiative that encourages physicians to become more involved in innovation in dermatology.

In recognition of the first anniversary of our Innovation column, Drs. Steve Xu and William Ju reflect on the range of topics covered throughout the year and highlight what's to come.

A central goal of Hacking Dermatology, one of the first ever dermatology-focused hackathons, is to build a community of people interested in collaborating to improve the current standards of care for patients with skin disease. Learn how to get involved in this article.

In this follow up to last month’s Innovations column on intellectual property and technology transfer, Raymond A. Miller, J.D., and Steve Xu, M.D., FAAD discuss how to utilize patents to maximize value for your venture.

In this month's Innovations column, Steve Xu, M.D., FAAD, begins the first part of a two-part mini-series discussing what innovators should know about intellectual property. This installment focuses on the different scenarios innovators may run into when dealing with the transfer of technological property, called technology transfer.

The Dermatology Innovation Forum, a one-day pre-AAD meeting, gives physicians a frontline seat to founder stories, new innovations and major advances happening currently in dermatology. Here are some of the highlights from the 2019 DIF conference.

In many ways, 2018 was a banner year for new novel drug approvals with 59 drugs approved by the FDA’s Center for Drug Evaluation and Research (CDER). Learn about the innovative drugs that were approved for dermatological indications in this article. 

Learn how the Food and Drug Administration (FDA) plays a critical role in the oversight of many medical devices used commonly in dermatology. 

Industry relationships are essential for innovation in dermatology. In this month's column, Steve Xu, M.D., and Michael L. Sierra, Ph.D., provide their insight on collaborating with industry.

What exactly is digital health? Dr. Steve Xu tackles this question in this month's Innovation column.

In this month's Innovation column, Steve Xu, M.D. and Morgan Nguyen discuss how to incorporate innovation into medical societies.

In this month's Innovation Column, Drs. Steve Xu and William Ju discuss the need for entrepreneurship education in medical school and residency training.

In this month's Innovation Column, Drs. Steve Xu and William Ju discuss the unique advantage dermatologists have when it comes to innovation in healthcare.

Introducing a new column called "Innovation" from the co-founders of Advancing Innovation in Dermatology Accelerator Fund. In the first installment of this series, Drs. Steve Xu and William Ju address the importance of innovation in dermatology.